Coating with a novel gentamicinpalmitate formulation prevents implant-associated osteomyelitis induced by methicillin-susceptible Staphylococcus aureus in a rat model
- 333 Downloads
Implant-associated osteomyelitis still represents a demanding challenge due to unfavourable biological conditions, bacterial properties and incremental resistance to antibiotic treatment. Therefore different bactericide or bacteriostatic implant coatings have been developed recently to control local intramedullary infections. Controlled local release of gentamicin base from a highly lipophilic gentamicin palmitate compound achieves extended intramedullary retention times and thus may improve its bactericide effect.
Forty male Sprague-Dawley rats were divided into two groups receiving an intramedullary femoral injection of 102 colony-forming units (CFU) of a common methicillin susceptible Staphylococcus aureus strain (MSSA Rosenbach) and either an uncoated femur nail (Group I) or a nail coated with gentamicin palmitate (Group II). Animals were observed for 28 and 42 days. Serum haptoglobin and relative weight gain were assessed as well as rollover cultures of explanted femur nails and histological scores of periprosthetic infection in dissected femurs.
Implants coated with gentamicin palmitate significantly reduced periprosthetic bacterial growth as well as signs of systemic inflammation compared with uncoated implants.
Gentamicin palmitate appears to be a viable coating for the prevention of implant-associated infections. These findings will have to be confirmed in larger animal models as well as in clinical trials.
KeywordsOsteomyelitis Rat model Gentamicin palmitate Coated implants Staphylococcus aureus
The present study was supported by Synthes GmbH, Umkirch, Germany. The authors thank Mr. Guido Schemken and his staff at the Central Animal Housing Facility in Marburg, as well as Prof. Dr. Markus Schofer and Dr. Stefan Lakemeier for their kind support in performing this study.
Conflict of interest
All authors declare that there is no conflict of interest.